GU Special Issue

UNTIL ONCOLOGISTS ARE ABLE to cure every case of bladder cancer, treatment won’t rise to the level we envision. But the development of therapies for people with the disease is moving in the right direction — and remarkably swiftly.

Cancergraph, a smartphone app, helps patients track their symptoms and report them to doctors.

A clinical trial will test whether partial prostate ablation matches radical prostatectomy in effectiveness — with fewer early side effects.

After a drop, the frequency of PSA screening for prostate cancer has stabilized.

Study: To prolong survival in early-stage prostate cancer that is low-risk, observe instead of operating.

A targeted drug for women with ovarian cancer may also benefit men with prostate cancer who have similar genetic mutations. A phase 3 trial is designed to find out.

The latest drugs for advanced kidney cancer are stirring optimism.

Scientists are looking for more and better ways to identify the prostate cancers that are most likely to become aggressive.

Immunotherapies known as checkpoint inhibitors are so promising in bladder cancer that many patients want them as first treatments — before they’ve been proven in that setting.